Tumor Detection by Imaging Proteolytic Activity

Molly R. Darragh¹, Eric L. Schneider², Jianlong Lou⁴, Paul J. Phojanakong³, Christopher J. Farady¹, James D. Marks⁴, Byron C. Hann³, and Charles S. Craik¹,²

Abstract

The cell surface protease membrane-type serine protease-1 (MT-SP1), also known as matriptase, is often upregulated in epithelial cancers. We hypothesized that dysregulation of MT-SP1 with regard to its cognate inhibitor hepatocyte growth factor activator inhibitor-1 (HAI-1), a situation that increases proteolytic activity, might be exploited for imaging purposes to differentiate malignant from normal tissue. In this study, we show that MT-SP1 is active on cancer cells and that its activity may be targeted in vivo for tumor detection. A proteolytic activity assay with several MT-SP1–positive human cancer cell lines showed that MT-SP1 antibodies that inhibit recombinant enzyme activity in vitro also bind and inhibit the full-length enzyme expressed on cells. In contrast, in the same assay, MT-SP1–negative cancer cell lines were inactive. Fluorescence microscopy confirmed the cell surface localization of labeled antibodies bound to MT-SP1–positive cells. To evaluate in vivo targeting capability, 0.7 to 2 nmoles of fluorescently labeled antibodies were administered to mice bearing tumors that were positive or negative for MT-SP1. Antibodies localized to MT-SP1–positive tumors (n = 3), permitting visualization of MT-SP1 activity, whereas MT-SP1–negative tumors (n = 2) were not visualized. Our findings define MT-SP1 activity as a useful biomarker to visualize epithelial cancers using a noninvasive antibody-based method. Cancer Res; 70(4); 1505–12. ©2010 AACR.

Introduction

Molecular imaging of cancer has the potential to facilitate early detection and to provide a more detailed assessment of disease. Currently, there are fewer than 10 imaging probes approved for use in the clinic, and they are often limited in use (1). Unfortunately, a lack of specificity and/or sensitivity limits most of these probes for use in evaluating patients with previously diagnosed cancers, and the majority are useful only in a small subset of cancers. Therefore, the search for new biomarker molecules, and for imaging probes with which to detect them, continues.

Proteases are a class of enzymes that shows promise for cancer detection and characterization. Proteolytic processing is necessary in nearly every stage of cancer growth and progression, from angiogenesis to extracellular matrix remodeling, cell-to-cell signaling, and metastasis (2–5). Finely regulated through activation and inhibition, changes in relative levels of proteases or their cognate inhibitors are often associated with cancer, suggesting that it is a dysregulation of proteolysis that contributes to malignant growth (4, 6).

Membrane-type serine protease 1 (MT-SP1), also referred to as matriptase, prostatin, TADG-15, PSS14, SNC19, and ST14, is a cell surface protease that, along with its cognate inhibitor hepatocyte growth factor activator inhibitor-1 (HAI-1), is dysregulated in a number of epithelial cancers. This dysregulation has been correlated to cancer stage, and the downregulation of inhibitors indicates that MT-SP1 is likely more active in the disease state (7–20). MT-SP1 has been shown to cleave a number of cancer-promoting substrates and has recently been associated with a prometastatic signaling pathway in breast cancer; however, its exact role in cancer has not been precisely defined (21–23). The ability to noninvasively monitor active MT-SP1 throughout disease progression would be useful for a better understanding of the role of MT-SP1 in tumor development and as a method for tumor detection.

The use of fluorescently labeled substrate-based probes in mouse models has confirmed that proteolytic activity is a viable marker for cancer imaging in vivo (24–27). Antibodies provide an alternate approach for targeting biomarkers and have the advantage of being very potent and specific for the target protease. Pharmacokinetics may also be altered by building the epitope recognition region into antibody-derived structures such as single chain variable fragments (scFv), Fabs, or minibodies. Human antibodies are also nonimmunogenic and can be functionalized for multiple imaging modalities. Accordingly, many antibody-derived tools for cancer detection and treatment are already Food and Drug Administration approved for in vivo use (1, 28).

MT-SP1, anchored to the extracellular surface of cancer cells, is localized to malignant tissue and accessible to antibodies, making it an ideal candidate for targeting in vivo. Phage display was used to isolate two antibodies that are...
selective for the active form of MT-SP1 and to inhibit the protease. Kinetic assays with a number of closely related proteases showed no measurable inhibition, indicating that these antibodies are also very selective for this enzyme (29, 30). Here, we show that MT-SP1 is active and can be inhibited on the surface of human cancer cells. Antibodies are then fluorescently labeled and used as probes for MT-SP1 activity in xenograft mice, ultimately showing that MT-SP1 is active at the tumor site and that this activity may be used for noninvasive tumor detection.

Materials and Methods

Protein Expression and Purification
E2 scFv and Fab and A11 Fab were expressed in Escherichia coli and purified as previously described (29, 31). Diabody was synthesized by complete deletion of the polyglycine linker region of the scFv, using the following primers (Eurofins MWG Operon): forward primer 5′-GGCCAAGGCACCCCTGTGACGGTTAAGCTCAGCGGA-TATCGTGATGACCCAGAGCCACTGAGCTCGCC-3′ and reverse primer 5′-GGCCAGGCTCGTGCTGGCTTGTCACATCGATATCCGCTGAGCTAACCGTCACCAGGGTGCCCTTGGCC-3′. The scFv expression vector was purified from E. coli using Miniprep kit (Qiagen) and subjected to PCR with primers, using reagents from Stratagene QuickChange kit (Agilent Technologies)—1 cycle at 97°C for 60 s, 20 cycles of 97°C for 60 s, 55°C for 80 s, 68°C for 5 min, and 1 cycle of 68°C for 12 min. The PCR product was sequenced to confirm deletion, retransformed into DH12S cells, and expressed in the same way as scFv. The K_i of the diabody was calculated as described below and found to be about twice that of the scFv. MT-SP1 and the inactive zymogen mutant R15A were expressed in E. coli and purified as described (29, 31). A11 IgG was expressed in Chinese hamster ovary cells using the V genes from the selected A11 Fab clone and an IgG expression vector as previously described (32).

Kinetics of Inhibition
The K_i for A11 IgG and E2 diabody was determined as previously described (30). The antibody was incubated with recombinant MT-SP1 for 4 h, and proteolysis was measured through activation of the chromogenic substrate Spectrozyme tPA (America Diagnostica, Inc.). A11 concentration was varied from 0 to 250 nmol/L, E2 diabody was varied from 3 to 250 pmol/L, and Spectrozyme concentration was varied from 0 to 1 mmol/L. The K_i value for each concentration of substrate was determined by fitting the data to the equation

\[ \frac{v_i}{v_s} = \left( \frac{[E_T] - I_T - K_i}{[E_T]} \right) + \sqrt{\frac{(I_T + K_i - E_T)^2 + (4K_i E_T)}{2E_T}} \]

where \( v_i \) is the reaction velocity in the presence of inhibitor and \( v_s \) is the reaction velocity without inhibitor for a given concentration of substrate. The K_i values were then plotted against substrate concentration to obtain the K_i:

\[ K_i = K_i \left( 1 + \frac{[S]}{K_m} \right) \]

Fluorescent Labeling of Protein
scFv, diabody, Fab, and IgG were labeled with AlexaFluor 594 (for microscopy) or AlexaFluor 680 (for in vivo imaging; Invitrogen) according to the manufacturer’s protocol. Protein was purified from unreacted dye on a Superdex 75 fast protein liquid chromatography column (GE Healthcare). Degree of labeling was determined using UV/Vis spectrometry as directed in the manufacturer’s protocol. In fluorescence experiments, concentrations given refer to dye molecules rather than the labeled protein.

Surface Plasmon Resonance
Binding curves were obtained as previously described, with the following modifications: the A11 Fab immobilization level was ~70 RU, and MT-SP1 and the inactive zymogen MT-SP1 R15A was injected in concentrations from 50 nmol/L to 1 μmol/L at 20 μL/min to minimize mass transfer effects (31). Surface regenerations were performed with 100 nmol/L glycine (pH 2.2), allowing a complete return to baseline. The sensorgram of the reference surface was subtracted from the ligand-conjugated surface for each injection.

Cell Culture
Human cancer cell lines HT-29, PC-3, MDA-MB-231, MCF-7, MDA-MB-468, HT1080, and COLO 320DM and LNCaP were obtained from the American Type Culture Collection and maintained in the recommended medium for less than 6 mo after receipt or resuscitation. MCF-7/Luc+ and MDA-MB-231/Luc+ cells were modified by lentiviral transduction to express Firefly luciferase as previously described (33, 34).

Activity assays. T-75 flasks of 70% to 90% confluent adherent cells were rinsed in PBS and lifted using Enzyme-Free Cell Dissociation Buffer (Invitrogen). Cells were washed twice in serum-free medium and counted, then resuspended in serum-free medium and aliquoted into round-bottomed 96-well plates, ranging from 30,000 to 60,000 cells per well, depending on the cell line. E2 Fab and serum-free medium were added for a final volume of 95 μL and final inhibitor concentration of 200 nmol/L. For total inhibition, 5 μL of 25× Complete Inhibitor Cocktail (Roche), a broad-spectrum protease inhibitor cocktail, in water were added along with 90 μL of serum-free medium. After 1- to 1.5-h incubation at 37°C, 5% CO2, Spectrofluor-tPA (American Diagnostica, Inc.) was added to a final concentration of 500 μmol/L. Fluorescence was measured on a SpectraMax Gemini EM plate reader (MDS, Inc.) with excitation/emission wavelengths of 380/460 nm. Fluorescence was measured for 1 h or until proteolysis ceased to be linear. Fluorescence was also measured.
in wells containing only 100 μL of serum-free medium to correct for nonproteolytically mediated substrate hydrolysis. Before inhibition assays, these experiments were carried out with 10,000 to 100,000 cells per well to ensure that the number of cells used was in the range in which fluorescence increased linearly with cell number. Activity assays were conducted in sextuplicate.

Fluorescence imaging. Glass microscope coverslips were flame-sterilized and placed in 12-well plates. Cells were passaged into these wells and grown to a confluence of 40% to 90%. Twelve to 16 h before imaging, cells were switched to serum-free medium. One hour before imaging, fresh serum-free medium was added with enough AlexaFluor 594-labeled E2 scFv to obtain a final fluorophore concentration of 300 nmol/L. Cells were returned to the incubator for 1 to 1.5 h, after which slides were removed, rinsed in PBS, and immediately imaged on a Nikon Eclipse E800 fluorescence microscope outfitted with a G-2E/C filter combination (Nikon). All cells were imaged within 10 min of removal from the incubator. For the HAI-1 blocking experiment, recombinant human HAI-1 (R&D Systems) at set intervals depending on the antibody construct injected. For IgG studies, two MCF-7 and one MCF-7/Luc+ mice were injected with ~2 nmol of dye (Fab) and ~3 nmol of dye (diabody). Images were collected in fluorescent mode on an IVIS 50 using Living Image 2.50.2 software (Caliper Life Sciences) at set intervals depending on the antibody construct injected. For IgG studies, two MCF-7 and one MCF-7/Luc+ mice were injected with ~2 nmol of dye and anesthetized and imaged at regular intervals for 50 h. Two MDA-MB-231/Luc+ tumor-bearing mice were injected with ~0.7 to 1 nmol of dye and imaged in the same manner. All dye was administered in total injection volume equal to 100–300 microliters. In the images presented, region of interest analysis of the entire mouse using Living Image software indicated the relative signal coming from each mouse 4 h after injection. Intensity minima and maxima of each set of the presented images were adjusted to compensate for the difference in total signal from the two sets of mice. For bioluminescent images, Luc+ mice were anesthetized as described and i.v. injected with ~1 mg of luciferase and images in bioluminescent mode on the IVIS 50 with Living Image software at 12 to 15 min post-injection. All in vivo studies were performed as directed under institutional approval.

### Results

Antibodies are selective for active MT-SP1. We have developed two antibodies, E2 and A11, that exclusively bind to the active form of MT-SP1 with picomolar affinity (29, 30). As

![Figure 1](image-url)
was shown for E2. we show here that the A11 Fab is selective for active MT-SP1 (Fig. 1; ref. 31). Mutating the arginine residue necessary for MT-SP1 autoactivation generates the inactive zymogen MT-SP1 R15A. Whereas binding of active MT-SP1 can be seen at 200 nmol/L, no binding was observed for MT-SP1 R15A at concentrations up to 1 μmol/L, demonstrating selectivity for the active enzyme.

Because they are both selective for active enzyme and share similar mechanisms of inhibition and potencies against MT-SP1, E2 and A11 are used interchangeably in these experiments, as summarized in Table 1. Although multiple antibody-based constructs are used—scFv, Fab, or IgG—they will be referred to throughout as “antibodies,” with the specific construct noted in Materials and Methods.

**Inhibition of MT-SP1 in cell culture.** Although the antibodies inhibit the catalytic domain of MT-SP1, it has not been shown that the full-length enzyme is active and can be inhibited by the antibodies on human cells. An assay was developed to address this by monitoring whole cell-associated proteolysis. In this assay, the P1-Arg-specific substrate Spectrofluor-tPA was added to cells in serum-free medium, and proteolysis was measured over time. When the MT-SP1–specific (α-MT-SP1) antibodies were added to these cells, any decrease in the rate of proteolysis could be attributed to this particular enzyme, confirming that MT-SP1 is active and that the antibodies inhibit the full-length protease.

Figure 2 shows the results of this assay as performed with seven different human cancer cells, chosen based on previously published mRNA expression data (35). The MT-SP1–positive cells showed a 42% to 89% decrease in proteolysis on the addition of antibody inhibitor, whereas the negative control lines MDA-MB-231 and COLO 320DM do not. Interestingly, the signal shows differences in the nature of this labeling; the HT-29 signal appears to come evenly from the membrane of the cell whereas the signal on LNCaP and MCF-7 cells is more punctate. Whether this is a result of MT-SP1 congregating on the surface or an internalization of the antibody/enzyme complex has not been determined. Nevertheless, these results show that these labeled antibodies serve as imaging probes to selectively target MT-SP1–positive cells *ex vivo*.

**Table 1. MT-SP1 inhibition constants of antibody constructs and their applications**

<table>
<thead>
<tr>
<th>Inhibitor</th>
<th>scFv</th>
<th>E2</th>
<th>Fab</th>
<th>A11</th>
<th>IgG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application</td>
<td>10 pmol/L</td>
<td>15 pmol/L</td>
<td>720 pmol/L</td>
<td>35 pmol/L</td>
<td></td>
</tr>
<tr>
<td>Inhibitor E2</td>
<td>Cell fluorescence</td>
<td>Cell-associated inhibition, <em>in vivo</em> imaging</td>
<td>Surface plasmon resonance</td>
<td><em>In vivo</em> imaging</td>
<td></td>
</tr>
</tbody>
</table>

Depending on the construct—scFv, diabody, Fab, or IgG—we were able to conjugate an average of one to six dye molecules per protein. Inhibition assays with recombinant protein showed minor (0- to 5-fold) increases in IC50 values, and given the high potency of these inhibitors, such an increase was not considered a significant barrier to antibody binding. To test the functionality of the scFv against full-length protein, human cancer cells were incubated with the labeled MT-SP1 antibodies and fluorescently imaged to look for association with the membranes of these cells (Fig. 3). Three MT-SP1–positive cell lines—HT-29, MCF-7, and LNCaP—show labeling with the fluorescent antibodies, whereas the negative control lines MDA-MB-231 and COLO 320DM do not.

**Ex vivo labeling of MT-SP1.** For an antibody to be useful as a probe for molecular imaging of MT-SP1 activity, it must be efficiently labeled without destroying its ability to bind to the enzyme. For fluorescence detection, commercially available dye–succinimidyl ester conjugates were used to nonspecifically label the antibodies through accessible lysines. Based on structural data of both A11 and E2 Fabs bound to recombinant MT-SP1, the labeling of free lysines should not interfere with enzyme binding (Supplementary Data Fig. S2).
MT-SP1 is putatively present on the surface of epithelial cells in at least three different forms—the inactive zymogen, active protease, and HAI-1–inhibited protease. Our experimental results indicate that the antibodies are binding to and inhibiting active protease on the cell surface; however, the question remains whether the antibody is displacing cognate inhibitor on binding. In this case, the signal would not be representative of free, active protease on the cell surface. A study of the rat homologues of MT-SP1 and HAI-1 observed picomolar inhibition, and MT-SP1, which has been shed from the cell surface, is found only in complex with its cognate inhibitor, suggesting extremely tight binding in vivo (36). To test for HAI-1 displacement by these antibodies, the immunofluorescence cell labeling was carried out with HT-29 cells, which were first incubated with recombinant HAI-1 (Fig. 3C and D). Cells that were treated with HAI-1 before the addition of fluorescently labeled scFv showed much lower membrane-associated fluorescence than those that were not treated. These data show that our antibodies only minimally displace HAI-1 under the conditions used in the fluorescence and the cell activity experiments, indicating that the majority of the signal comes from free active MT-SP1.

**Targeting MT-SP1 in vivo.** Having successfully labeled active MT-SP1 in cell culture, the antibodies were evaluated as probes for MT-SP1 activity in vivo. Based on cell culture data, xenograft mouse models were generated using MCF-7, MCF-7/Luc+, and MDA-MB-231/Luc+ breast cancer cell lines. The "Luc+" designation indicates that the cells have been transfected with an imaging vector that includes the gene for Firefly luciferase so that the tumor can be imaged through bioluminescence detection independent of MT-SP1–based fluorescence detection (34). These mouse models were injected with fluorescently labeled diabody, Fab, or IgG, and imaged for up to 50 hours to assess biodistribution of antibodies and any tumor localization. The anti–MT-SP1 diabody and Fab localized to the tumor in MCF-7 xenograft mice but failed to achieve high tumor/background contrast due to high levels of signal retained in the excretory system (Supplementary Data Fig. S3). The IgG, however, localized to the tumor in both MCF-7 and MCF-7/Luc+ mice and remained so until free protein was cleared, achieving excellent tumor to background contrast by 50 hours (Fig. 4A; Supplementary Data Fig. S4). Similar injections into MDA-MB-231/Luc+ tumor-bearing mice showed no tumor-associated signal over the same period (Fig. 4B). Luciferin administered to these mice generated a tumor-specific signal, validating both the presence of the MCF-7/Luc+ and MDA-MB-231/Luc+ cells at this location and sufficient vasculature to deliver the signal.
labeled antibodies to the tumor. These experiments indicate that MT-SP1 is active in the tumors that are positive for MT-SP1 expression, and that this activity can be targeted in vivo for noninvasive cancer imaging using the antibodies as probes.

Discussion

Proteases have long been recognized as cancer biomarkers; however, based on indications that it is activity that is important for cancer progression, perhaps a more direct strategy for disease assessment is to measure the active form of the enzyme. The approach described here, from phage display to in vivo imaging, could be readily applied to any number of cancer-associated proteases, particularly those anchored to the cell membrane, to identify additional sites for targeting tumors in vivo.

The tools described here may have many uses in studying MT-SP1 both in the laboratory and the clinic. Although immunohistochemistry and expression data have strongly connected MT-SP1 to cancer, these experiments have focused on overall protein levels rather than the amount of proteolytic activity. The antibody-mediated targeting of active MT-SP1 described here may provide a new way to measure protease activity and connect it with specific downstream effects both in cell culture and in mouse models, such as the recently proposed prometastatic signaling pathway involving MT-SP1, the growth factor MSP, and its receptor RON (22, 23).

These antibodies may also prove useful for studying the biology of MT-SP1 at the cellular level. Recent results have shown that HAI-1 recycles between the membranes of polarized epithelial cells, and it is proposed that MT-SP1 may be transported between membranes in a similar fashion, perhaps in complex with HAI-1 (37). Although further studies are necessary, it is possible that the punctuate fluorescence observed when the labeled antibodies are added to unfixed MCF7 and LNCaP cells is a result of internalization of antibody-bound enzyme, indicating that MT-SP1 is indeed capable of reentering the cell after it is exocytosed to the extracellular membrane.

MT-SP1 detection and inhibition may also find use in the clinic. Small-molecule inhibitors of MT-SP1 have shown that in vivo inhibition has potential in anticancer therapy (38). Antibodies could achieve similar results while allowing for more specific targeting and inhibition, minimizing toxicity. As an imaging biomarker, MT-SP1 expression has been correlated with cancer stage and/or subtype, and a noninvasive method for assessing the activity in the malignant tissue may aid in tumor classification and potential therapeutic design. Independent of the utility of MT-SP1 inhibition in cancer therapy, it can be used as an imaging biomarker to assess tumor margin or monitor tumor response to alternative therapies in MT-SP1–positive tumors.

Previous studies connecting MT-SP1 and related type 2 transmembrane serine proteases to cancer have suggested their potential as biomarkers (39). This work shows that MT-SP1 activity is present in tumors and can be targeted and inhibited on the surface of cancer cells using specific antibodies, validating an approach that can be used to target cell surface proteolysis for cancer assessment and intervention.

Figure 4. α-MT-SP1 antibodies are able to selectively target MT-SP1–positive tumors in vivo. AlexaFluor 680–labeled A11 IgG was injected and imaged using a two-dimensional fluorescence imager. Tumors are indicated by arrows. In MCF-7/Luc+ xenograft mice, the tumors become selectively labeled with minimal background after 50 h (A). In the MDA-MB-231/Luc+ (MT-SP1–negative) models, however, no tumor labeling was seen over the same period (B). As an alternate method for detecting the tumors, mice were injected with ~2 mg of luciferin and imaged after 10 to 15 min. Because the Luc+ cells have been engineered to express luciferase, a bioluminescent signal is seen at the tumor, confirming location and viability of the xenograft.
Disclosure of Potential Conflicts of Interest

The authors declare no competing commercial interest with the work presented here.

Acknowledgments

We thank Lily Darragh for technical consultation and Dr. Mark Moasser for useful discussions and critical reading of the manuscript.

References


Grant Support

National Science Foundation Graduate Research Fellowship (Chih Family Foundation Award, and ARCS Foundation Scholarship (M.R. Darragh), Department of Defense Breast Cancer Research Program BC043343 (C.J. Faradaj), and NIH grants CA72006 and CA125765 (C.S. Craik) and CA10846-04 (E.L. Schneider). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 5/8/09; revised 12/1/09; accepted 12/3/09; published OnlineFirst 2/9/10.


Tumor Detection by Imaging Proteolytic Activity


Cancer Res  Published OnlineFirst February 9, 2010.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-09-1640

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2010/02/08/0008-5472.CAN-09-1640.DC1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.